Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Director Lewis Clayton Jr. Cantley sold 4,000 shares of the company’s stock in a transaction dated Wednesday, August 23rd. The shares were sold at an average price of $56.85, for a total transaction of $227,400.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Lewis Clayton Jr. Cantley also recently made the following trade(s):

  • On Wednesday, July 19th, Lewis Clayton Jr. Cantley sold 3,500 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $56.14, for a total transaction of $196,490.00.
  • On Thursday, July 20th, Lewis Clayton Jr. Cantley sold 9,000 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $56.36, for a total transaction of $507,240.00.
  • On Wednesday, June 14th, Lewis Clayton Jr. Cantley sold 2,000 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $50.87, for a total transaction of $101,740.00.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) opened at 57.08 on Friday. The company’s 50 day moving average is $57.70 and its 200 day moving average is $52.91. Agios Pharmaceuticals, Inc. has a 52 week low of $35.84 and a 52 week high of $67.74. The stock’s market cap is $2.76 billion.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.78) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.57) by $0.21. Agios Pharmaceuticals had a negative return on equity of 68.15% and a negative net margin of 502.12%. The business had revenue of $11.30 million for the quarter, compared to the consensus estimate of $10.68 million. During the same period in the previous year, the company posted ($1.47) earnings per share. Agios Pharmaceuticals’s revenue for the quarter was up 62.1% compared to the same quarter last year. Equities analysts predict that Agios Pharmaceuticals, Inc. will post ($7.07) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/08/26/lewis-clayton-jr-cantley-sells-4000-shares-of-agios-pharmaceuticals-inc-agio-stock.html.

A number of hedge funds have recently bought and sold shares of the company. Swiss National Bank boosted its stake in Agios Pharmaceuticals by 3.4% in the first quarter. Swiss National Bank now owns 55,360 shares of the biopharmaceutical company’s stock worth $3,233,000 after buying an additional 1,800 shares during the last quarter. Spark Investment Management LLC boosted its stake in Agios Pharmaceuticals by 139.9% in the second quarter. Spark Investment Management LLC now owns 84,700 shares of the biopharmaceutical company’s stock worth $4,357,000 after buying an additional 49,400 shares during the last quarter. Geode Capital Management LLC boosted its stake in Agios Pharmaceuticals by 8.3% in the first quarter. Geode Capital Management LLC now owns 263,899 shares of the biopharmaceutical company’s stock worth $15,410,000 after buying an additional 20,336 shares during the last quarter. Hamilton Lane Advisors LLC acquired a new stake in Agios Pharmaceuticals during the second quarter worth about $2,890,000. Finally, Clear Harbor Asset Management LLC acquired a new stake in Agios Pharmaceuticals during the first quarter worth about $270,000. 83.13% of the stock is owned by institutional investors and hedge funds.

Several analysts have issued reports on the stock. SunTrust Banks, Inc. reaffirmed a “buy” rating and issued a $80.00 price target (up previously from $68.00) on shares of Agios Pharmaceuticals in a report on Tuesday, August 8th. Oppenheimer Holdings, Inc. reaffirmed an “outperform” rating and issued a $83.00 price target (up previously from $75.00) on shares of Agios Pharmaceuticals in a report on Thursday, August 10th. Cann reaffirmed a “buy” rating and issued a $75.00 price target on shares of Agios Pharmaceuticals in a report on Sunday, June 11th. Leerink Swann raised shares of Agios Pharmaceuticals from a “market perform” rating to an “outperform” rating and upped their price target for the company from $50.00 to $80.00 in a report on Wednesday, August 2nd. Finally, Janney Montgomery Scott reaffirmed a “hold” rating on shares of Agios Pharmaceuticals in a report on Tuesday, August 1st. Four analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $74.75.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Insider Buying and Selling by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Stock Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.